IKT-703

N/A

Report date: 2025/01/26 18:48:13

Base Information

Drug NameIKT-703

Drug Alias NameCAR T-cell therapy (Icell Kealex Therapeutics)PD-L1-VV-loaded CAR T-cell therapy (Icell Kealex Therapeutics)PD-L1 Checkpoint Inhibitor-Expressing CAR T-Cell Therapy (Icell Kealex Therapeutics)IKT-703

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIcell Kealex Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesIcell Kealex Therapeutics

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A